A Phase II Clinical Trial of YH23537 in Patients With Chronic Periodontal Disease.

Inclusion Criteria: * Subjects must be 19 years of age or older * Have at least 18 natural teeth * have been diagnosed with chronic periodontitis * have been diagnosed Mild/Moderate/Severe periodontitis with according to CDC / AAP periodontal classification (2012)) * Provide informed consent and willingness to cooperate with the study protocol Exclusion Criteria: * Women of childbearing potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study and for up to 4 weeks after the last dose of investigational product. * Pregnant or lactating females * Systemic diseases such as diabetes and hypertension * Patients who take Anticoagulants or Antiplatelet Agents * Continually use for phenytoin, calcium channel blocker, cyclosporin, coumarin, nonsteroidal anti-inflammatory drugs and aspirin use in the previous one month * Patients who received periodontal treatment within the last 6 months * Patients who have malignant tumor * History of positive serologic evidence of current infectious liver disease including HbsAg, or anti-HCV. * Patients with mental retardation and dementia